| 摘要 |
<p>598656 The disclosure relates to an ophthalmic drug delivery system comprising (a) a delivery vehicle containing a phospholipid or a mixture of phospholipids selected from the group consisting of DOPC, POPC, SPC, EPC, PEG-DSPE and DOPG, and cholesterol, wherein cholesterol is present in an amount of 10-33 molar percent relative to the delivery vehicle; and (b) an antagonist specific to VEGF selected from a group consisting of an antibody specific to VEGF, a VEGF receptor, a nucleic acid and a small molecule; wherein 50-90% of the antagonist is in non-associated form, and the weight ratio of the phospholipid and cholesterol in combination to the antagonist is 5-80:1. The antibody specific to VEGF may be bevacizumab and the drug delivery system may further comprise a corticosteroid.</p> |
